%0 Journal Article %1 Roodhart.2008 %A Roodhart, J. M. %A Langenberg, M. H. %A Witteveen, E. %A Voest, E. E. %D 2008 %J Curr.Clin.Pharmacol. %K & A Agents Angiogenesis Animals Antibodies Antineoplastic Blood Coagulation Diseases Disorders Endothelial Factor Growth Humans Hypertension Hypothyroidism Inhibitors Intestinal Medical Nervous Oncology Perforation Proteinuria Receptors Signal System Transduction Tyrosine Vascular adverse antagonists chemically drug effects induced inhibitors pathology therapeutic therapy toxicity use %N 2 %P 132-143 %T The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway %U PM:18690886 %V 3 %X Vascular Endothelial Growth Factor (VEGF) is considered to be one of the most important regulators of angiogenesis and a new key target in anti-cancer treatment. Various clinical trials have validated the clinical importance of anti-VEGF or anti-VEGF receptor (VEGFR) therapy. Currently the humanized monoclonal antibody bevacizumab (blocks VEGF-A), and the tyrosine kinase inhibitors sunitinib and sorafenib (inhibit VEGFRs) are approved for patients with various malignancies and several others are expected in the coming years. Unfortunately, anti-VEGF/VEGFR treatment is not void of side effects. An array of unexpected side effects is now seen in clinical practice. Management of these side effects is extremely important in the development of the various anti-VEGF/VEGFR therapies and their optimal use. This review provides an overview of the toxicity profile of this class of agents, the molecular basis behind these side effects and indicates potential options for management. VEGF and its r

@article{Roodhart.2008, abstract = {Vascular Endothelial Growth Factor (VEGF) is considered to be one of the most important regulators of angiogenesis and a new key target in anti-cancer treatment. Various clinical trials have validated the clinical importance of anti-VEGF or anti-VEGF receptor (VEGFR) therapy. Currently the humanized monoclonal antibody bevacizumab (blocks VEGF-A), and the tyrosine kinase inhibitors sunitinib and sorafenib (inhibit VEGFRs) are approved for patients with various malignancies and several others are expected in the coming years. Unfortunately, anti-VEGF/VEGFR treatment is not void of side effects. An array of unexpected side effects is now seen in clinical practice. Management of these side effects is extremely important in the development of the various anti-VEGF/VEGFR therapies and their optimal use. This review provides an overview of the toxicity profile of this class of agents, the molecular basis behind these side effects and indicates potential options for management. VEGF and its r}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Roodhart, J. M. and Langenberg, M. H. and Witteveen, E. and Voest, E. E.}, biburl = {https://www.bibsonomy.org/bibtex/28b3e295f504b5479b4c999d5c9badab8/kanefendt}, interhash = {1917b90c504be5485af6abf95899950f}, intrahash = {8b3e295f504b5479b4c999d5c9badab8}, journal = {Curr.Clin.Pharmacol.}, keywords = {& A Agents Angiogenesis Animals Antibodies Antineoplastic Blood Coagulation Diseases Disorders Endothelial Factor Growth Humans Hypertension Hypothyroidism Inhibitors Intestinal Medical Nervous Oncology Perforation Proteinuria Receptors Signal System Transduction Tyrosine Vascular adverse antagonists chemically drug effects induced inhibitors pathology therapeutic therapy toxicity use}, number = 2, pages = {132-143}, timestamp = {2010-02-05T11:28:50.000+0100}, title = {The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway}, url = {PM:18690886}, volume = 3, year = 2008 }